cagrilintide tirzepatide combination trial Efficacy and safety of co-administered once-weekly 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 Retatrutide + Cagrilintide Benefits: 4

The approval, announced on 23 July 2024, has made semaglutide the first weight loss drug to be prescribed to prevent cardiovascular events such as cardiovascular death, non-fatal heart attack and non-fatal stroke in people with established cardiovascular disease and a BMI higher or equal to 27kg/m 2

Long-Term Skin Health Maintenance: Preserves youthful skin and prevents future damage

Patients with diverticular disease should maintain high-fibre intake, adequate hydration and monitor for new or worsening abdominal pain

This is why professional guidance is essential, stacking without proper monitoring can cause more harm than good